Attached files
file | filename |
---|---|
EX-10.1 - MATERIAL CONTRACTS - Q BioMed Inc. | stockoptionagreement.htm |
8-K - PRIMARY DOCUMENT - Q BioMed Inc. | a8-kqbiopanicuccifeb2018d.htm |
Q BioMed: Former Novartis Global Head and WuXi STA's VP
of Pharmaceutical Development Joins Company
Board
NEW
YORK, February 13, 2018 /PRNewswire/ —
Q
BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is
pleased to welcome Dr. Rick Panicucci as an independent member on
its board of Directors.
Dr.
Rick Panicucci is the Vice President of Pharmaceutical Development
at STA Pharmaceutical Co. Ltd. (A WuXi AppTec Company). He is
responsible for providing scientific leadership in the areas of
Developability, Formulation Development and GMP Manufacturing. Rick
has been providing formulation and development support to Mannin
Research on Man01, our glaucoma drug candidate.
Prior
to WuXi he held the position of Global Head of Chemical and
Pharmaceutical Profiling (CPP) at Novartis from 2004 to 2015, where
he led the development and implementation of innovative dosage form
designs and continuous manufacturing paradigms. He worked closely
with Novartis BD&L and Venture Fund on many external deals such
as Proteus Digital Health, MicroChips, 7th Sense Bio, West Pharma,
Unilife, MIT and the University of Toronto to mention a few. He has
also held positions as the Director of Formulation Development at
Vertex Pharmaceuticals and Senior Scientist at Biogen.
Denis
Corin, Q BioMed Chairman and CEO, said, “Rick has played an
important role in the early stages of drug discovery and deal
making for various companies. We are very pleased to have him join
our board and welcome the vast experience and oversight he
brings.” Mr Corin adds, “Having Rick join us as an
independent Director, is an important corporate governance step as
we seek to uplist to a national exchange this
year.”
Dr.
Panicucci received his Ph.D. in Physical Organic Chemistry at the
University of Toronto, and has two post doctoral fellowships at the
University of California at Santa Barbara and the Ontario Cancer
Institute.
Forward-Looking Statements:
This
press release may contain “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
growth strategy and product development programs and any other
statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and
are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock
price. Factors that could cause actual results to differ materially
from those currently anticipated are: risks related to our growth
strategy; risks relating to the results of research and development
activities; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; uncertainties
relating to preclinical and clinical testing; our dependence on
third-party suppliers; our ability to attract, integrate, and
retain key personnel; the early stage of products under
development; our need for substantial additional funds; government
regulation; patent and intellectual property matters; competition;
as well as other risks described in our SEC filings. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in our expectations or any changes in
events, conditions or circumstances on which any such statement is
based, except as required by law.
Contact:
Denis
Corin
CEO
Q
BioMed Inc.
+1-888-357-2435
SOURCE
Q BioMed Inc.